0 467

Cited 8 times in

Subfoveal choroidal thickness in idiopathic choroidal neovascularization and treatment outcomes after intravitreal bevacizumab therapy

Authors
 Kim, Hyesun  ;  Lee, Kahyun  ;  Lee, Christopher Seungkyu  ;  Byeon, Suk Ho  ;  Lee, Sung Chul 
Citation
 RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, Vol.35(3) : 481-486, 2015 
Journal Title
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
ISSN
 0275-004X 
Issue Date
2015
MeSH
Adolescent ; Adult ; Angiogenesis Inhibitors/therapeutic use* ; Antibodies, Monoclonal, Humanized/therapeutic use* ; Bevacizumab ; Choroid/pathology* ; Choroidal Neovascularization/drug therapy* ; Choroidal Neovascularization/physiopathology ; Female ; Fluorescein Angiography ; Humans ; Intravitreal Injections ; Male ; Middle Aged ; Organ Size ; Retrospective Studies ; Subretinal Fluid ; Tomography, Optical Coherence ; Treatment Outcome ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Visual Acuity/physiology
Keywords
bevacizumab ; central subfield thickness ; enhanced depth imaging optical coherence tomography ; idiopathic choroidal neovascularization ; subfoveal choroidal thickness
Abstract
PURPOSE: To determine subfoveal choroidal thickness in idiopathic choroidal neovascularization (CNV) and evaluate visual and anatomical outcomes in patients with idiopathic CNV after intravitreal bevacizumab.

METHODS: Retrospective observation case series. Seventeen eyes of 17 patients with idiopathic CNV were treated with a single intravitreal bevacizumab injection, followed by additional doses based on optical coherence tomography findings, including intraretinal fluid, subretinal fluid, or pigment epithelial detachment. We analyzed best-corrected visual acuity, central subfield thickness, and subfoveal choroidal thickness at presentation and final visit. Seventeen unaffected fellow eyes and 17 healthy eyes constituted the control group for subfoveal choroidal thickness.

RESULTS: The subfoveal choroidal thickness was significantly thinner in eyes with idiopathic CNV (237.59 ± 53.84 μm) than in the unaffected fellow eyes (281.71 ± 59.01 μm, P = 0.001) or normal control eyes (290.38 ± 58.94 μm, P = 0.028). Mean logarithm of the minimum angle of resolution best-corrected visual acuity improved from 0.46 initially to 0.26 after treatment (P = 0.024). Mean central subfield thickness decreased from 387.88 ± 97.52 μm at baseline to 261.41 ± 31.18 μm after treatment (P < 0.001).

CONCLUSION: Subfoveal choroidal thickness is reduced and may be associated with the pathophysiology of idiopathic CNV. Intravitreal bevacizumab resulted in significant visual and anatomical improvement in patients with idiopathic CNV.
Full Text
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&AN=00006982-201503000-00015&LSLINK=80&D=ovft
DOI
10.1097/IAE.0000000000000354
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Ophthalmology (안과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Hye Sun(김혜선)
Byeon, Suk Ho(변석호) ORCID logo https://orcid.org/0000-0001-8101-0830
Lee, Ga Hyun(이가현)
Lee, Sung Chul(이성철) ORCID logo https://orcid.org/0000-0001-9438-2385
Lee, Christopher Seungkyu(이승규) ORCID logo https://orcid.org/0000-0001-5054-9470
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/139718
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links